伽玛刀放射外科治疗肾细胞癌脑转移患者的更新肾分级预后评估(GPA)的验证。

Validation of the updated renal graded prognostic assessment (GPA) for patients with renal cancer brain metastases treated with gamma knife radiosurgery.

机构信息

Department of Internal Medicine/Medical Oncology, Elisabeth-TweeSteden Hospital, Tilburg, The Netherlands.

Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, The Netherlands.

出版信息

J Neurooncol. 2021 Jul;153(3):527-536. doi: 10.1007/s11060-021-03793-9. Epub 2021 Jun 25.

Abstract

INTRODUCTION

Prognosis of patients with brain metastasis (BM) from renal cell carcinoma (RCC) is relevant for treatment decisions and can be estimated with the Renal Graded Prognostic Assessment (GPA). The aim of this study is to validate the updated version of this instrument in a cohort treated with Gamma Knife radiosurgery (GKRS) without prior local intracerebral therapy.

METHODS

Between 2007 and 2018, 106 RCC patients with BM were treated with GKRS. They were categorized according to the updated Renal GPA. Overall survival (OS), distant intracranial failure and local failure were estimated using the Kaplan-Meier method and risk factors were identified with Cox proportional hazard regressions.

RESULTS

Median OS was 8.6 months. Median OS for GPA categories 0.0-1.0 (15%), 1.5-2.0 (12%), 2.5-3.0 (35%) and 3.5-4.0 (29%) was 2.9, 5.5, 8.1 and 20.4 months, respectively. Karnofsky performance status < 90, serum hemoglobin ≤ 12.5 g/dL, age > 65 years and time from primary diagnosis to brain metastasis < 1 year were significantly related with shorter survival, while presence of extracranial disease, the volume and total number of BM had no significant impact on OS. A total count of > 4 BM was the only predictive factor for distant intracranial failure, while none of the investigated factors predicted local failure.

CONCLUSIONS

This study confirms the updated Renal GPA in an independent cohort as a valuable instrument to estimate survival in patients with BM from RCC treated with GKRS.

摘要

介绍

肾细胞癌(RCC)脑转移(BM)患者的预后与治疗决策相关,可以通过肾脏分级预后评估(GPA)进行评估。本研究的目的是在未接受颅内局部治疗的情况下,使用伽玛刀放射外科(GKRS)治疗的患者队列中验证该工具的更新版本。

方法

2007 年至 2018 年,106 例 RCC 伴 BM 患者接受 GKRS 治疗。他们根据更新的肾 GPA 进行分类。使用 Kaplan-Meier 方法估计总生存期(OS)、远处颅内失败和局部失败,并使用 Cox 比例风险回归识别危险因素。

结果

中位 OS 为 8.6 个月。GPA 类别 0.0-1.0(15%)、1.5-2.0(12%)、2.5-3.0(35%)和 3.5-4.0(29%)的中位 OS 分别为 2.9、5.5、8.1 和 20.4 个月。卡氏功能状态<90、血清血红蛋白≤12.5g/dL、年龄>65 岁和从原发性诊断到脑转移<1 年与生存时间较短显著相关,而存在颅外疾病、BM 的体积和总数对 OS 无显著影响。BM 总数>4 是远处颅内失败的唯一预测因素,而所研究的因素均不能预测局部失败。

结论

本研究在独立队列中证实了更新后的肾 GPA 是一种评估 RCC 伴 BM 患者接受 GKRS 治疗后生存的有价值的工具。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索